Yesintek (ustekinumab-kfce) — Medica
Psoriatic arthritis
Initial criteria
- age > 6 years
- medication is prescribed by or in consultation with a rheumatologist or a dermatologist
Reauthorization criteria
- patient has been established on the requested drug for at least 6 months
- when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline OR improvement in at least one symptom or disease activity score (e.g., DAPSA, CPDAI, PsA DAS, Grace Index, LEI, SPARCC, Leeds Dactylitis Instrument Score, MDA, PsAID-12, or serum markers)
Approval duration
initial: 6 months; reauth: 1 year